SFI
KZIA

Susquehanna Fundamental Investments’s Kazia Therapeutics KZIA Stock Holding History

Susquehanna Fundamental Investments’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-232
Closed -$144K – 1715
2021
Q1 		$144K Sell
232
-160
-41% -$83.7K ﹤0.01% 1432
2020
Q4 		$170K Buy
+392
New +$156K ﹤0.01% 1377

Other funds holding KZIA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TW
Transform Wealth Greenwood Village, Colorado $1.65B AUM 19.1% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Susquehanna Fundamental Investments's KZIA Position: Q2 2021 in Review

Susquehanna Fundamental Investments sold out of Kazia Therapeutics (KZIA) in Q2 2021, closing a stake of 232 shares — an estimated $144K sold.

Susquehanna Fundamental Investments first reported a position in KZIA in Q4 2020 and held it in 2 quarters. The position peaked at $170K in Q4 2020. 12 funds tracked by Wall St. Rank hold KZIA as of Q2 2021.

  • Susquehanna Fundamental Investments reported no remaining Kazia Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 232 Kazia Therapeutics shares in Q2 2021, an estimated $144K.
  • Susquehanna Fundamental Investments first reported a position in Kazia Therapeutics in Q4 2020 and held it in 2 quarters.
  • Susquehanna Fundamental Investments's Kazia Therapeutics position peaked at $170K in Q4 2020.
  • 12 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q2 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2021, filed 11 Aug 2021.